New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia.

ABSTRACT: The treatment of acute myeloid leukemia (AML) has evolved over the past few years with the advent of next-generation sequencing. Targeted therapies alone or in combination with low-dose or high-intensity chemotherapy have improved the outcome of patients with AML treated in the frontline and relapsed/refractory settings. Despite these advances, allogeneic stem cell transplantation (allo-HCT) remains essential as consolidation therapy following frontline treatment in intermediate-and adverse-risk and relapsed/refractory disease. However, many patients relapse, with limited treatment options, hence the need for post-transplant strategies to mitigate relapse risk. Maintenance therapy following allo-HCT was developed for this specific purpose and can exploit either a direct anti-leukemia effec

SUBMITTER: Mohty R 

PROVIDER: S-EPMC9890036 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature